Cleveland Clinic
Cleveland Clinic

(c) Cleveland Clinic

Fat attenuation index

Biomarker helps to predict coronary inflammation

Researchers at Cleveland Clinic, University of Oxford, and University of Erlangen have identified a novel imaging biomarker – and found it can be used to predict all-cause and cardiac mortality by measuring inflammation of fatty tissue surrounding the coronary arteries.

Coronary artery inflammation inhibits fatty tissue formation surrounding the blood vessels, known as perivascular fat. Researchers developed the perivascular fat attenuation index (FAI) as an imaging biomarker to quantify inflammation-induced changes in perivascular fat. FAI captures coronary inflammation by mapping the changes in perivascular fat on coronary computed tomography angiography (CTA), enabling early detection of coronary inflammation.

“This is an exciting new technology which has the potential for providing a simple, non-invasive answer to detect patients at risk for future fatal heart attacks, said co-first author Milind Desai, M.D., a cardiologist at Ohio-headquartered Cleveland Clinic. “More importantly, it highlights the incredible value of cross-continent collaboration to validate the findings in different populations.”

The team behind the study, Cardiovascular Risk Prediction using Computed Tomography (CRISP-CT), collected data from two cohorts of consecutive patients undergoing coronary CT angiography — 1,872 patients in Germany from 2005 to 2009 (derivation cohort) and 2,040 patients at Cleveland Clinic from 2008 to 2016 (validation cohort). The median patient age of the cohorts was 62 and 53 years.

In both cohorts, higher perivascular FAI values — indicating greater coronary inflammation — were associated with significantly higher rates of death from any cause and death from cardiac causes. “This new technology may prove transformative for primary and secondary prevention. For the first time we have a set of biomarkers, derived from a routine test that is already used in everyday clinical practice, that measures what we call the ‘residual cardiovascular risk’, currently missed by all risk scores and non-invasive tests,” said Charalambos Antoniades, M.D., who led the study at the University of Oxford’s Division of Cardiovascular Medicine. “Knowing who is at increased risk for a heart attack could allow us to intervene early enough to prevent it. I expect these biomarkers to become an essential part of standard CT coronary angiography reporting in the coming years.”

Manifesting primarily as heart attacks and strokes, cardiovascular diseases (CVDs) take the lives of 17.7 million people every year – 31% of all global deaths – according to the World Health Organization.

11.09.2018

Read all latest stories

Related articles

Nano-scale diagnostics

Researchers are developing a ‘Lab-on-skin’ to monitor biomarkers

Move over, lab-on-a-chip and lab-on-paper. There’s a new diagnostic technology in research labs that is gaining credibility. It is called lab-on-skin technology and some scientists are quite…

Mass spectometry

Strategies to advance cancer biomarkers

Cancer biomarker testing represents an important element of the clinical biochemistry service, yet progress in this area in the last two decades has been slow.

Biobank

Frozen samples are scientists’ gold

Our knowledge of causes and mechanisms of current and future diseases is on ice – not the perpetual ice of the polar caps but artificial ice. It is stored in biobanks at -80 to -160 °C.

Related products

Research use only (RUO)

Eppendorf - Mastercycler nexus X2

Eppendorf AG

LIS, Middleware, POCT

i-SOLUTIONS Health - LabCentre

i-SOLUTIONS Health GmbH

LIS, Middleware, POCT

Medat - Laboratory Information System

Medat Computer-Systeme GmbH

Research use only (RUO)

SARSTEDT - Low DNA Binding Micro Tubes

SARSTEDT AG & CO.

Research use only (RUO)

Shimadzu - CLAM-2000

Shimadzu Europa GmbH